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Abstract
In the present study we have compared the effects of leucine supplementation and its metabolite β-hydroxy-β-methyl
butyrate (HMB) on the ubiquitin-proteasome system and the PI3K/Akt pathway during two distinct atrophic conditions,
hindlimb immobilization and dexamethasone treatment. Leucine supplementation was able to minimize the reduction
in rat soleus mass driven by immobilization. On the other hand, leucine supplementation was unable to provide
protection against soleus mass loss in dexamethasone treated rats. Interestingly, HMB supplementation was unable
to provide protection against mass loss in all treatments. While solely fiber type I cross sectional area (CSA) was
protected in immobilized soleus of leucine-supplemented rats, none of the fiber types were protected by leucine
supplementation in rats under dexamethasone treatment. In addition and in line with muscle mass results, HMB
treatment did not attenuate CSA decrease in all fiber types against either immobilization or dexamethasone
treatment. While leucine supplementation was able to minimize increased expression of both Mafbx/Atrogin and
MuRF1 in immobilized rats, leucine was only able to minimize Mafbx/Atrogin in dexamethasone treated rats. In
contrast, HMB was unable to restrain the increase in those atrogenes in immobilized rats, but in dexamethasone
treated rats, HMB minimized increased expression of Mafbx/Atrogin. The amount of ubiquitinated proteins, as
expected, was increased in immobilized and dexamethasone treated rats and only leucine was able to block this
increase in immobilized rats but not in dexamethasone treated rats. Leucine supplementation maintained soleus
tetanic peak force in immobilized rats at normal level. On the other hand, HMB treatment failed to maintain tetanic
peak force regardless of treatment. The present data suggested that the anti-atrophic effects of leucine are not
mediated by its metabolite HMB.
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Introduction
Bed rest, denervation, hind limb unloading, microgravity,
immobilization, elevated secretion of catabolic hormones (e.g.
glucocorticoids), and pharmacologic treatment (e.g.
dexamethasone) might result in considerable muscle wasting.
The well known deleterious consequences of these conditions
include decreased muscle fiber cross-sectional area and
protein content, reduced force and power output, increased
fatigability and increased insulin resistance [1,2]. However, the
molecular mechanisms responsible for muscle wasting are still
not completely understood [3,4].
Much attention has been given to intracellular pathways
associated with muscle mass control such as Akt-mTOR,
Myostatin and the Ubiquitin-proteasome system (UPS) [5-8].
Evidence suggests that the enhancement of proteolysis in
atrophying muscles results mainly from a general activation of
the UPS protein degradation [9-11]. In various types of muscle
wasting, including Cushing’s syndrome [12], diabetes [13],
sepsis [14], cancer cachexia [15], and renal failure [16],
muscles exhibit a common series of adaptations, which include
increased content of ubiquitin-protein conjugates [17] and of
mRNA encoding ubiquitin [18], certain ubiquitination enzymes
[13], and multiple proteasome subunits [16,19].
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The UPS is an ATP-requiring multienzymatic process that
mediates protein degradation by the proteasome. Briefly, prior
to degradation a target protein undergoes a three-step process,
which covalently links a polyubiquitin chain to the substrate.
Three enzymatic components are involved in this process: E1
(ubiquitin-activating enzyme), E2 (Ub-conjugating enzymes)
and E3 (ubiquitin protein ligase), which presents substrate
recognition sites [20,21]. The ubiquitinated substrate can then
be recognized and degraded by the proteasome. In wasting
conditions, the genes Mafbx (muscle atrophy F-box) /atrogin-1
and muscle ring finger 1 (MuRF1), both encoding E3 ubiquitin
ligases, are up-regulated [9,22], mainly through FOXO
transcription factors [23,24]. In addition, the UPS activity is also
influenced by a family of enzymes known as deubiquitinating
enzymes (DUB’s) [25]. These enzymes can destabilize the
covalent bond formed between polyubiquitin chain and
substrate [25]. The role of DUBs in skeletal muscle plasticity is
elusive; up to date only one study has determined gene
expression of DUBs during longitudinal skeletal muscle growth
[26].
In addition to mechanical stimuli and hormonal profile,
certain nutritional strategies (e.g. amino acids supplementation)
also modulate protein turnover in skeletal muscle [27,28]. It is
well known that leucine per se can promote an acute increase
in protein synthesis; however, its effects upon degradation
pathways are still poorly understood. It is known that elevation
of mRNA of atrogenes (~3 days after immobilization) and
consequently muscle mass loss (clearly detected at 7 days
after immobilization) can be minimized by leucine
supplementation, although the precise mechanisms remain to
be elucidated [29-32]. A previous study showed [32] that
leucine feeding in a protein deprivation model minimizes
protein catabolism without affecting expression of atrogenes.
These authors suggest that the down regulation of the
lysosomal pathway activity, rather than UPS, is preferentially
involved in the protective effect of a leucine enriched diet [32].
Although the protein deprivation efficiently activates muscle
mass degradation pathways, this experimental model is not
best designed for investigating the localized effects of disuse
on muscle mass since systemic metabolic effects of protein
deprivation might play a major role.
Beta-hydroxy-beta-methyl butyrate (HMB) is a metabolite
derived from leucine. Under normal conditions ~5% of leucine
is converted to HMB and there is experimental evidence
supporting that supplementation of this metabolite plays a role
in increased performance and muscle hypertrophy. On the
other hand the role of HMB in skeletal muscle wasting is still
poorly understood. Although HMB has been shown to minimize
muscle wasting in cachexia models, no study has addressed
the impact of HMB in localized muscle wasting promoted by
disuse. Additional effects conferred to HMB include: protection
against skeletal muscle injury, minimization of muscle protein
degradation, increase in GH-IGF-1 axis activity and modulation
of IGF-1 expression in muscle, leading to enhancement of
mTOR pathway activity (See Zanchi et al. [33] for review) [34].
Although it has been shown that HMB stimulates myogenic
differentiation and survival via PI3K/AKT pathway [35], it is still
unclear whether HMB could modulate this pathway under
atrophic conditions.
Our hypothesis contemplates that HMB could play a
contributive role in the anti-atrophic effects of leucine, therefore
we have compared the effects of leucine and HMB during hind
limb immobilization and dexamethasone treatment,
representing respectively localized and systemic models of
muscle wasting. The results showed a specific protective effect
of leucine during hind limb immobilization and no effect of HMB
in both hind limb immobilization and dexamethasone treatment,
pointing that HMB does not mediate the anti-atrophic effects of
leucine. Furthermore, this study indicates the idea that
minimization of the UPS activation is a major player in
protection against atrophy in the dexamethasone/
immobilization models.
Materials and Methods
The protocols used in this study are in agreement with
ethical principles in animal research followed by the Brazilian
College of Animal Experimentation and were approved by the
Institute of Biomedical Sciences / University of São Paulo -
Ethical Committee for Animal Research (# 151/12).
Animals and supplementations
Male Wistar rats (n=256, n=8 per group) (~2 months-old)
weighing 260±25 g were housed in standard plastic cages in
an animal room with controlled environmental conditions and
maintained on standard food and water ad libitum.
Leucine (L-Leucine, Ajinomoto©, Tokyo, Japan) was orally
administered (via gavage) once a day in a dose of 2.7 g/kg
body mass per day (modified from Kimball and Jefferson [36]),
starting 3 days prior to immobilization or dexamethasone
treatment. A control group received saline only.
HMB (Calcium β-Hydroxy-β-Methylbutirate, Lonza©, Basel,
Switzerland) was orally administered (via gavage) once a day
in a dose of 600mg/kg/day, starting 3 days prior to
immobilization or dexamethasone treatment. A control group
received saline only.
The supplementations effects per se were analyzed using
animals supplemented for 1, 4 and 6 days without atrophic
conditions and pre-charge.
Immobilization procedure and dexamethasone
treatment
Monolateral hind limb immobilization was performed in the
left hind limb by applying a cast with total plantar extension,
knee was kept in total extension, as previously reported
[29,37].
Eight groups of animals were submitted to atrophic
conditions and analyzed 1, 2, 3 and 7 days after immobilization
(Imob 1d, 2d, 3d and 7d) or dexamethasone treatment (Dexa
1d, 2d, 3d and 7d). Another eight groups received leucine or
HMB starting 3 days prior to immobilization which was
maintained up to the end of the experiment (Imob 1d+Leu,
Imob 2d+Leu, Imob 3d+Leu and Imob 7d+Leu ; Imob 1d+HMB,
Imob 2d+HMB, Imob 3d+HMB; Imob 7d+HMB). To analyze the
effect of leucine and HMB under hormonal atrophy, eight
Leucine and HMB in Skeletal Muscle
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groups received leucine or HMB starting 3 days prior to
dexamethasone treatment which was maintained up to the end
of the experiment (Dexa 1d+Leu, Dexa 2d+Leu, Dexa 3d+Leu
and Dexa 7d+Leu ; Dexa 1d+HMB, Dexa 2d+HMB, Dexa 3d
+HMB; Dexa 7d+HMB).
Tissue samples
Soleus muscles were exposed and used for in vivo
contraction assays and after that were removed and weighed.
Subsequently, these muscles were transversely cut in half; one
segment was immersed in cold isopentane for 30 seconds,
cooled in liquid nitrogen and stored at -70°C for histochemistry.
The other segment was snap frozen in liquid nitrogen and
stored at -70°C for RNA and protein expression analysis.
Histochemistry and cross-sectional area
The frozen muscles were cut into 10-µm cross-sections
through the proximal to distal region using a cryostat (Leica©
CM3050, Nussloch, Germany). Alternate serial cross-sections
were obtained in the proximal and middle regions of both
muscles incubated for myofibrillar ATPase activity after alkali
(ATPase, pH 10.3) or acid pre-incubation (ATPase, pH 4.3)
[38,39]. After classification, the cross-section area was
obtained from approximately 2000 muscle fibers and shown as
mean±s.d. The cross-sectional area was determined using a
microscope (Nikon Eclipse E600©, Fukuoka, Japan) equipped
with a digital video camera and image software (Metamorph®,
Universal Imaging Corporation©, Downingtown, USA).
In vivo contraction assays
All groups submitted to immobilization or dexamethasone
treatment for 7 days were tested for muscle function prior to
euthanasia. With the animal sedated, the distal tendon of the
soleus muscle of the right hind limb was exposed and attached
to the lever arm of a servomotor (BIOPAC Systems, Goleta,
CA, USA). The knee of the right hind limb was fixed and then
muscle twitch contractions were induced by electrical
stimulation of the sciatic nerve. The muscle length was
adjusted to produce a maximum twitch force in a single twitch
(stimulation at 4 V). The muscle length that produced the
maximum twitch force was considered the optimum muscle
length. With the muscle in optimum length, tetanic force was
induced at a stimulation frequency of 250 Hz at 4 V. Data were
collected using Acknowledge software (BIOPAC Systems,
version 3.9.1.6 for Windows).
RNA isolation
Muscle samples (25 mg) were homogenized with a Polytron©
(Kinematica AG, Littau-Lucerne, Switzerland) and total RNA
was isolated using the Trizol reagent (Invitrogen©, Carlsbad,
USA) following the manufacturer’s recommendations. These
samples were dissolved in free ultra-filtered water, and their
concentrations were determined by measuring the optical
density at 260 nm with an Eppendorf© spectrophotometer
(Eppendorf©, Hamburg, Germany). The purity of the RNA was
determined by calculating the absorbance ratio at 260 nm and
280 nm and RNA integrity was checked on a 1% agarose gel
stained with ethidium bromide.
Reverse transcription (RT) reaction
One µg of the total RNA was used in a reaction containing
oligo dT (500 µg/ml), 10 mM of each dNTP, 5X First-Strand
Buffer, 0.1 M DTT and 200 U of reverse transcriptase
(SuperScript II-Invitrogen©, San Diego, USA). RT reaction was
performed at 70 °C for 10 min followed by 42 °C for 60 min and
10 min at 95 °C.
Oligonucleotide primers
Primer sets for rat Mafbx/Atrogin-1(Foward-
TACTAAGGAGCGCCATGGATACT, Reverse-
GTTGAATCTTCTGGAATCCAGGAT), UBP45 (Forward-
CAGCATGCGTACCTCCTACACC, Reverse-
ACTCTTTGAATTCTTGGCTTTGTTGA), UBP69 (Forward-
CCGGACACAGCCCATGAG, Reverse-
GTAGCGGGACGATTCTGTATAGC), USP28 (Forward-
AAAGGCCAGTAATGGTGACATCA, Reverse-
GTCGTGACTGGGCTCCTTAACT) and Cyclophilin A
(Forward-GCCGATGACGAGCCCTTG, Reverse-
TGCCGCCAGTGCCATTAT) were designed using the Primer
Express Software 2.0 (Applied Biosystems©, Foster City, USA).
Primer sequences for Murf-1 (Forward-
TGACCAAGGAAAACAGCCACCAG, Reverse-
TCACTCCTTCTTCTCGTCCAGGATGG) were obtained from
Wray et al. [40]. All primers were synthesized by IDT©
(Coralville, USA).
Quantitative polymerase chain reaction (PCR)
For each gene, PCR was performed in duplicate with a 25 µl
reaction volume of 5-20 ng of cDNA, 12.5 µl Syber Green
Master Mix© (Applied Biosystems©) and 50-200 nM of each
primer. PCR analyses were carried out using the following
cycle parameters: 50°C for 2 min, 95°C for 10 min, followed by
40 cycles of 95°C for 15 s, and 60°C for 1 min. The
fluorescence intensity was quantified and amplification plots
were analyzed with a Corbett RotorGene 6000 (Qiagen©,
Hilden, Germany). Results were expressed using the
comparative cycle threshold (CT) method as described in the
User Bulletin 2 from the manufacturer (Applied Biosystems©,
Foster City, USA). ΔCt values were calculated in every sample
for each gene of interest as follows: Ctgene of interest - Ctreporter gene;
with Cyclophilin A as the control gene. Relative changes in the
expression level of one specific gene (ΔΔCt) were calculated
by subtraction of the ΔCt from the control group (used as a
calibrator) to the corresponding ΔCt from the treated groups.
Western blotting analysis
The primary antibodies used for Western blotting were: rabbit
polyclonal antibodies against ubiquitin (1:1,000; cat# A-100;
BostonBiochem©, Cambridge, USA), PI3K (1:1,000; cat# 4255;
Cell Signaling), AKT (1:1,000; cat# 9272; Cell Signaling),
phospho-AKT Thr308 (1:1,000; cat# 4056S; Cell Signaling),
phospho-AKT Ser473 (1:1,000; cat# 4058S; Cell Signaling),
4E-BP1 (1:1,000; cat# 9644; Cell Signaling) and monoclonal
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mouse antibody against Sarcomeric Actin (1:1,000; cat#
M0874; Dako©, Glostrup, Denmark). The secondary antibodies
used were alkaline-phosphatase conjugate goat anti-rabbit IgG
(1:1,000; cat# D0487; Dako©, Glostrup, Denmark) and rabbit
anti-mouse IgG (1:1000; cat# D0314; Dako©, Glostrup,
Denmark).
Soleus muscles were homogenized in an extraction
solubilization buffer (50 mM potassium phosphate buffer (pH
7.0), 0.3 M sucrose, 0.5 mM DTT, 1 mM EDTA (pH 8.0), 0.3
mM PMSF, 10 mM NaF), and phosphatase inhibitor cocktail
(1:100; Sigma-Aldrich©, St. Louis, USA) or RIPA buffer (0.625%
Nonidet P-40, 0.625% sodium deoxycholate, 6.25 mM sodium
phosphate, 1 mM EDTA pH 7.4) containing 10 µg/ml of
protease inhibitor cocktail (Sigma-Aldrich©, St. Louis, USA) in
order to detect the expression of ubiquitin conjugating protein.
Homogenates were centrifuged at 10,000g for 10 min at 4°C
and the supernatant used. Protein concentration was
determined by Bradford assay (Bio-Rad©, Hercules, USA) with
bovine serum albumin as standard.
Equal amounts of protein (50 µg) were run on 12% SDS-
PAGE and transferred to a nitrocelulose membrane (Biorad©,
Hercules, USA). The membranes were stained with Ponceau S
to confirm the protein amount and then rinsed with Tween Tris-
buffered saline solution (0.5 M NaCl, 50 mM Tris-HCl, pH 7.4
and 0.1% Tween 20). All membranes were incubated with
0.1% Tween 20 in 0.1 M phosphate-buffered saline (PBS, pH
7.4) at room temperature. Membranes were then incubated
overnight with primary antibodies at 4°C. After a 15-min wash
in Tween Tris-buffered saline solution, membranes were
incubated with alkaline-phosphatase (AP) conjugated
secondary antibody for 1 hour at room temperature and
washed again for 15 min in Tween Tris-buffered saline solution.
After washing, speciﬁc bands were visualized by enzymatic
colorimetric NBT/BCIP (Roche, Mannheim, Germany). Loading
variations were monitored by sarcomeric actin Western
immunoblotting [41].
Statistical analysis
Multiple comparisons of mean values were performed using
analysis of variance (ANOVA) and a post-hoc Tukey’s test to
compare mean values when appropriate. For all comparisons,
a p<0.05 was considered significant.
Results
The first aim of the present study was to compare the impact
of HMB and leucine treatment upon skeletal muscle mass in
two wasting models, dexamethasone and hind limb
immobilization. One week under dexamethasone treatment, as
expected, caused about 35% soleus muscle mass loss,
interestingly administration of either HMB or leucine was
unable to change the effect of dexamethasone (Figure 1A). As
expected, immobilization induced about 40% soleus muscle
mass loss and in contrast to the dexamethasone model, we
found differential protective effects of HMB and leucine. While
HMB was unable to slow down soleus muscle mass loss,
leucine was able to keep soleus muscle mass loss at similar
levels when compared to control group (Figure 1B).
In order to get further insight on the effects of HMB and
leucine upon skeletal muscle under atrophy, the cross sectional
area of specific fiber types was determined. Under our
experimental conditions, dexamethasone promoted a drop in
the cross sectional area only in type II fibers. In addition neither
HMB nor leucine were able to counteract this effect (Figure 2A
and B). Immobilization also promoted a decrease in the cross
sectional area of type I and type II muscle fibers, interestingly
leucine but not HMB was able to protect type I muscle fibers
from cross sectional area loss. Neither leucine nor HMB were
able to protect type II fibers against cross sectional area loss
(Figure 2D).
In addition to morphological measurements, the muscle
function after leucine and HMB treatments was investigated in
rats submitted to dexamethasone and immobilization. As
expected, both dexamethasone and immobilization induced a
severe drop (~70%) in single twitch and tetanic force (Figure
3). While HMB was completely ineffective to restore muscle
force, leucine was able to fully revert the decrease in muscle
force driven by immobilization, but not by dexamethasone
treatment (Figure 3).
Next gene expression of E3 ligases and deubiquitinases in
rats submitted to dexamethasone and immobilization was
evaluated. The two molecular hallmarks of atrophic state
Mafbx/Atrogin-1 and MuRF1 were differentially regulated by
leucine and HMB per se (Figure 4A and B). While leucine per
se was overall not able to strongly stimulate expression of
neither one of those genes, HMB increased (~6 fold)
expression of Mafbx/Atrogin-1 peaking at the 1st day of
treatment and returning to basal levels at 4th day of treatment
(Figure 4A). The deubiquitinases were also differentially
expressed by leucine and HMB. UBP 69 was up regulated by
both leucine (~3.5 fold) and HMB (~2.5 fold) at short periods of
supplementation (Figure 4C). While UBP 45 gene expression
was down regulated by leucine (~0.1 fold), it was up regulated
by HMB (~4 fold, Figure 4D). USP 28 gene expression was
unaffected by leucine and up regulated by HMB (~2.5 fold,
Figure 4F). After depicting the effect of leucine and HMB per
se, we investigated the impact of those in rats under
dexamethasone and immobilization. For that purpose, rats
were preloaded with either HMB or Leucine for 3 days in order
to assure full effectiveness and also to set the dexamethasone/
immobilization treatment in a time frame where effects of HMB
and Leucine per se were minimized (time zero in Figures 5 and
6 is equivalent to 3 days of treatment in Figure 3).
Dexamethasone increased Mafbx/Atrogin-1 and MuRF1 gene
expression (2-3 fold) at 1st day of treatment regardless of either
HMB or leucine administration (Figure 5A and C). At second
and third days, on the other hand, leucine was able to return
Mafbx/Atrogin-1 gene expression to control levels. Differently,
HMB was able to return Mafbx/Atrogin-1 to control levels only
on the 3rd day of dexamethasone treatment (Figure 5A). Neither
leucine nor HMB were able to decrease the positive effect of
dexamethasone upon MuRF1 gene expression (Figure 5C).
The gene expression of both Mafbx/Atrogin-1 and MuRF1
increased up to 2nd to 3rd days of immobilization (Figure 5B and
D). Leucine, but not HMB, was able to return Mafbx/Atrogin-1
and MuRF1 to control levels on the 3rd day of immobilization
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(Figure 5B and D). It is noticeable, however, that unexpectedly
HMB treatment enhanced MuRF1 gene expression in
immobilized muscles when compared to control (Figure 5B).
Regarding deubiquitinases, the impact of leucine and HMB
upon dexamethasone treated and immobilized rats was rather
minor (Figure 6). Nonetheless, HMB was able to increase
UBP45 gene expression in rats on the 2nd day of immobilization
(Figure 6D). Leucine was able to increased gene expression of
USP28 in dexamethasone treated animals (Figure 6E). Also
leucine was able to increase USP28 gene expression on the
2nd and 3rd days of immobilization (Figure 6F).
Figure 1.  Soleus muscle mass.  Soleus muscle mass (grams) 7 days post either hormonal treatment (Dexa 7d; A) or hind limb
immobilization (Imob 7d; B). Rats were supplemented with either HMB (Dexa 7d+HMB; A and Imob 7d+HMB; B) or Leucine (Dexa
7d+Leu; A and Imob 7d+Leu; B). a, p<0.05 vs control, b - p<0.05 vs. Imob. Bars represent mean+SD.
doi: 10.1371/journal.pone.0076752.g001
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In order to understand the overall state of ubiquitination, an
antibody, which detects mono and poliubiquitinated proteins,
was utilized. The results show that as expected,
dexamethasone increases the abundance of ubiquitinated
proteins (Figure 7). Interestingly, neither leucine, nor HMB
were able to counteract this effect. Immobilized animals also
showed elevated levels of ubiquitinated proteins (Figure 7).
While Leucine treatment effectively counteracted the increase
in ubiquitinated proteins induced by immobilization, HMB
partially decreased ubiquitination levels as compared to control
(Figure 7).
In an attempt to clarify whether leucine and HMB activate the
PI3K/AKT pathway during atrophic conditions, the levels of key
proteins on this pathway were analyzed. The results showed a
strong decrease on PI3K levels during dexamethasone
administration and immobilization (p<0,05 vs. Control, Figure
8A, B and C). Interestingly, under leucine or HMB treatments,
the effect of dexamethasone administration and immobilization
upon PI3K levels was attenuated. The levels of total AKT were
not altered by either dexamethasone or immobilization and
AKT phosphorylation at Thr308 was not affected by both
dexamethasone and leucine. On the other hand, HMB was
Figure 2.  Cross sectional area from fiber types I and II.  Soleus muscle fibers cross sectional area (CSA, µm2) of fiber types I
and II 7 days post either dexamethasone treatment (A and B) or hind limb immobilization (C and D). a- p<0.05 vs. Control; b -
p<0.05 vs. Imob. Bars represent Mean+S.D.
doi: 10.1371/journal.pone.0076752.g002
Leucine and HMB in Skeletal Muscle
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Figure 3.  Effect of HMB and leucine supplementation under single twitch and tetanic force during atrophic stimuli.  Single
twitch force (in grams) and Tetanic peak force (in grams) in animals submitted to dexamethasone treatment or hind limb
immobilization. White bars represent Mean±SD in Control group; black bars represent Mean±SD in Dexa, Dexa+HMB and Dexa
+Leu groups; Striped bars represent Mean±SD in Imob, Imob+HMB and Imob+Leu groups. a- p<0.05 vs. Control; b - p<0.05 vs.
Imob.
doi: 10.1371/journal.pone.0076752.g003
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able to increase Thr308 phospho-AKT levels in
dexamethasone treated animals (p<0.05 vs. Control, Figure 8A
and B). AKT phosphorilation at Ser473 was reduced by
dexamethasone/immobilization and remained reduced despite
of either leucine or HMB supplementation (p<0.05 vs Control,
Figure 8A, B and C). 4E-BP1 levels were unchanged by
immobilization/dexamethasone and also unresponsive to either
leucine or HMB (Figure 8).
Discussion
In this study, we have shown that HMB is not able to provide
protection against skeletal muscle wasting in rats submitted to
two different atrophy inducing models, dexamethasone
treatment and immobilization. In contrast, leucine acts as an
efficient protector only in the immobilization model, acting on
type I fibers.
HMB is an important metabolite derived from leucine and
about 5% of leucine is endogenously converted to HMB [42].
Although previous studies have shown that HMB can exert
important effects upon skeletal muscle [43,44], no studies have
systematically compared the effects of HMB and leucine in
skeletal muscle under catabolic conditions. Such a study is of
high interest to understand the individual effects of HMB,
isolating on what is leucine dependent and HMB dependent
regarding skeletal muscle trophicity. In this sense, the present
study complements a previous study [29], which showed that
leucine supplementation successfully protects skeletal muscle
against wasting in rats, submitted to immobilized hind limb. At
that point, we were not able to determine whether HMB could
also act as an anti-wasting agent. Herein, the results of the
present study clearly indicate that HMB does not play a role in
the skeletal muscle anti-wasting effect driven by leucine
supplementation since 1) HMB does not exert protection
against skeletal muscle mass loss as leucine in immobilized
animals, 2) HMB does not minimize the rise in atrogenes gene
expression in immobilized animals and 3) HMB does not
minimize loss of force in immobilized animals. Interestingly, a
recent study has pointed out that HMB supplementation does
improve skeletal muscle performance i.e. tetanic force,
although the authors have not detected increases in skeletal
muscle mass [44]. These results combined with the results of
the present study emphasize the notion that the hypertrophic
and atrophic states are not the result of a continuum controlled
by the same pathways, those states seem to be also under the
control of different mechanisms. It should be noted though, that
in the study of Pinheiro et al. [44], a different dose and time of
treatment were employed as compared to the present study.
Nonetheless it is possible to envision that HMB would be more
related to activating pro-hypertrophic/anabolic pathways, rather
than inhibiting pro-atrophic/catabolic ones.
Previous studies have addressed the effects of HMB in
skeletal muscle mass. Hao et al. [45] showed that HMB in a
hind limb suspension model, in line with our observations, is
unable to prevent atrophy (i.e. skeletal muscle mass). On the
other hand, in contrast with the results presented herein, the
same authors detected that HMB provides a protective effect
upon fiber cross sectional area and isometric force loss
induced by hind limb suspension (Hao et al. 2011). This
controversy might be related to response variation in different
species (Wistar Rats in present study vs Fisher 344x Brown
Norway rats in Hao et al. study [45]) and age (2 month old
animals in the present study vs 34 month olds in Hao et al.
study [45]). It is widely recognized that skeletal muscle atrophy
is much more severe in elders, and that certain mechanisms
play a more important role, such as apoptosis. In fact Hao et al.
Figure 4.  Atrogenes and deubiquitinating enzymes gene expression during HMB or leucine supplementation per se.  Gene
expression of Atrogin-1 (A), MuRF1 (B), UBP69 (C), UBP45 (D) and USP28 (E) during leucine (filled line -1, 4 and 6 days) or HMB
(dashed line -1, 4 and 6 days) supplementation. Control is arbitrarily set to 1. Data are expressed as mean±S.D. (n=5 per group). a-
p<0.05 vs. Control; b - p<0.05 vs. Leu.
doi: 10.1371/journal.pone.0076752.g004
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[45] found that apoptosis is significantly minimized in
atrophying HMB supplemented animals. Therefore, it is
possible to consider that HMB could be more effective in elder
rats, acting throughout minimization of apoptosis. A recent
study using L6 cells, showed that HMB is able to minimize the
increase in atrogenes induced by dexamethasone,
nonetheless, no in vivo experiments were conducted [43].
These previous studies along with the present investigation
foresee additional work to pinpoint the effectiveness of HMB as
an anti-atrophic agent.
HMB per se, exerts surprising effects in non-immobilized
muscles. Interestingly, Mafbx/Atrogin-1 gene expression is
sharply induced (~6 fold) by HMB, while leucine has no effect
(Figure 4). Although not responsive to HMB, MuRF1, as one
could expect, is down regulated by leucine per se (~40%) in
intact muscles, clearly showing differential effects. It is not
possible to point out the biological meaning of this strong
positive effect of HMB upon Mafbx/Atrogin-1 in intact muscles.
Several studies have shown that HMB does not drive atrophy
[43,44], actually, it is clearly related with ergogenic effects [46].
We speculate that the strong rise in Mafbx/Atrogin-1 driven by
HMB might be counteracted by a rise in deubiquitinases
(Figure 4). Another possibility contemplates a compensatory
down regulation of other elements of the proteasome system
such as E2 and proteasome subunits [47,48].
While in the present study, both dexamethasone and
immobilization consistently boosted mRNA levels of atrogenes,
deubiquitinases did not seem to follow a pattern. For example,
UBP69 gene expression was up regulated in dexamethasone
treated animals and down regulated in immobilization (Figure
6). UBP 45 gene expression was elevated in dexamethasone
treated animals and unaltered in immobilization. These data
suggest that those genes might not be quite linked to an
atrophying program and might be more related to other cellular
processes.
One of the key findings of the present study regards the
differential effects of leucine upon atrophying skeletal muscle
under dexamethasone and immobilization regimens. Leucine
supplementation clearly is a potent anti-wasting agent in
immobilized muscles, on the other hand rather ineffective in
animals under dexamethasone regimen. Considering it is
known that leucine acts through minimizing the increase in
atrogenes during atrophy in the immobilization model but does
not accomplish this effect in dexamethasone treated animals,
one could interpret that the immobilization and dexamethasone
might include modulation of atrogenes throughout different
Figure 5.  Effect of HMB and leucine supplementation under E3 ligases gene expression during atrophic stimuli.  Gene
expression of Atrogin-1 (A and B) and MuRF1 (C and D) during either dexamethasone treatment (A and C) or hind limb
immobilization (B and D). Control is arbitrarily set to 1. Data are expressed as mean±S.D. (n=5 per group). a- p<0.05 vs. Control; b -
p<0.05 vs Dexa or Imob in respective time point; c - p<0.05 vs. Imob+HMB in respective time point.
doi: 10.1371/journal.pone.0076752.g005
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mechanisms. Regarding FOXO activity previous studies
indicate that FOXO1 and FOXO3a seem to be similarly
activated (dephosphorylated) by both dexamethasone and
immobilization [49,50]. Another possibility includes that co-
factors able to modulate FOXO transactivation capacity could
be targeted by leucine in the immobilization condition and not
in the dexamethasone condition. A candidate for such a
function is for example p300; which is an acetyltransferase
known to inhibit FOXO [51]. Other candidates could be Stress-
Activated Protein Kinases (SAPKs). Those factors are known
to transfer FOXO3a from nucleus to cytoplasm [52]. Other
possibilities include differential effects of immobilization and
dexamethasone in FOXO independent pathways such as NF-
κB [53,54], which are also able to trigger atrogenes.
Figure 6.  Effect of HMB and leucine supplementation under deubiquitinating enzymes gene expression during atrophic
stimuli.  Gene expression of UBP69 (A and B), UBP45 (C and D) and USP28 (E and F) during either dexamethasone treatment (A,
C and E) or hind limb immobilization (B, D and F). Control is arbitrarily set to 1. Data are expressed as mean±S.D. (n=5 per group).
a- p<0.05 vs. Control; b - p<0.05 vs Dexa or Imob in respective time point; c - p<0.05 vs. Dexa+HMB or Imob+HMB in respective
time point.
doi: 10.1371/journal.pone.0076752.g006
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We have observed that dexamethasone drives loss of mass,
which is not followed by a mirrored loss of muscle fiber CSA
while in the immobilization model there is a good correlation
between mass loss and CSA drop. Although we do not have a
precise explanation for this difference in response, it is possible
that the acute systemic effects of dexamethasone play a role,
i.e. potent diuresis and natriuresis [55], resulting in muscle
dehydration.
Another key question not yet answered raised by the present
study is how leucine is able to minimize the increased
atrogenes expression driven by immobilization. One possibility
contemplates a direct effect of leucine upon PI3K/AKT. In fact,
it has been previously shown that leucine can directly activate
mTOR, a downstream molecule [27,56], suggesting that
leucine could modulate this pathway. Our results clearly show
that leucine is able to minimize the down regulation of certain
elements of PI3K/AKT pathway during atrophy induced by
dexamethasone treatment and immobilization, such as PI3K.
On the other hand downstream elements of this pathways
evaluated in the present study were not influenced by leucine
treatment, suggesting that the decrease in PI3K/AKT pathway
activity driven by immobilization cannot be mitigated by leucine.
In fact, in a previous study we observed that immobilized rats
supplemented with leucine do not exhibit increased protein
synthesis rate as compared to immobilization alone [29],
suggesting that the effects of leucine upon the PI3K/AKT
pathway observed in the present study do not reflect in
increased protein synthesis. It is not to be excluded that the
modulation of certain elements of the PI3K/AKT pathway could
help upon the minimization of UPS activation. In fact, it has
been shown that AKT can inhibit FOXO activity, potentially
acting as an anti-atrophic agent per se [24]. Analysis of the
leucine metabolite HMB in the present study also corroborates
the concept that minimization of UPS plays a major anti-
atrophic role; we have found that although HMB is, similarly to
leucine, able to improve PI3K/AKT activity during atrophy, it
cannot protect skeletal muscle against loss of mass and
function. Likewise, HMB is unable to minimize UPS activation
during atrophy.
In summary, we have shown that HMB has no role in
protecting skeletal muscle atrophy in the immobilization and
dexamethasone models. Leucine however, provides a strong
anti-atrophic effect in the immobilization model, and these
effects are probably independent of leucine conversion to
HMB. It would be of interest in future studies to compare the
protective effects of leucine in other models involving skeletal
muscle atrophy, such as cancer, AIDS and renal failure.
Figure 7.  Total ubiquitinated proteins levels.  Representative Western blot of ubiquitin-protein conjugates 3 days after
dexamethasone treatment or hind limb immobilization, under HMB (Dexa+HMB and Imob+HMB, respectively) or leucine
supplementation (Dexa+Leu and Imob+Leu, respectively). Each lane represents one of three independent experiments (n=3 per
group).
doi: 10.1371/journal.pone.0076752.g007
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Figure 8.  Effect of HMB and leucine under PI3K/AKT protein levels during atrophic stimuli.  Representative protein level of
PI3K, AKT total, AKT phosphorilation residues at Thr308 and Ser473 and 4E-BP1, 3 days after dexamethasone administration or
hind limb immobilization, under leucine (Dexa+Leu and Imob+Leu, respectively) or HMB (Dexa+HMB and Imob+HMB, respectively).
Each pair of lanes represents a duplicate of each group (n=4 per group). Sarcomeric actin was used as loading control. The bars in
B and C represent mean±S.D. a -p<0,05 vs. Control.
doi: 10.1371/journal.pone.0076752.g008
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